Objective: To determine whether individuals with concurrent active psychiatric disease and chronic hepatitis C virus (HCV) can be treated safely and effectively with interferon-alpha. Design: Prospective, open label study. Setting: Tertiary referral hospital. Patients: Thirty-one consecutive patients with co-existent chronic HCV and a psychiatric illness. Interventions: Interferon-alpha was administered at doses of either 5 MU three times per week for 6 months (n = 17) or 5 MU daily for 6 months (n = 14). Methods: HCV-RNA in serum was measured using reverse transcriptase polymerase chain reaction. Serum alanine aminotransferase levels were assessed and liver biopsy was performed before and after 6 months of treatment and again after 6 months of follow-up. Results: Twenty-nine of the 31 patients completed 6 months of therapy. Two patients discontinued therapy after 2 and 3 months of treatment. Serum alanine aminotransferase levels returned to normal in 22 (71%) patients. Fifteen (48%) of the 31 patients cleared HCV-RNA from their serum. Only four patients experienced a worsening of their psychiatric illness during treatment. Interferon therapy was discontinued in two of these patients. Conclusions: Patients with a co-existent psychiatric illness and chronic HCV can be treated successfully with interferon-alpha with the active participation of a psychiatrist and the maintenance of psychotropic drug therapy during interferon treatment.

Van Thiel, D., Friedlander, L., Molloy, P., Fagiuoli, S., Kania, R., & Caraceni, P. (1995). Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 7(2), 165-168.

Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness.

Fagiuoli S;
1995

Abstract

Objective: To determine whether individuals with concurrent active psychiatric disease and chronic hepatitis C virus (HCV) can be treated safely and effectively with interferon-alpha. Design: Prospective, open label study. Setting: Tertiary referral hospital. Patients: Thirty-one consecutive patients with co-existent chronic HCV and a psychiatric illness. Interventions: Interferon-alpha was administered at doses of either 5 MU three times per week for 6 months (n = 17) or 5 MU daily for 6 months (n = 14). Methods: HCV-RNA in serum was measured using reverse transcriptase polymerase chain reaction. Serum alanine aminotransferase levels were assessed and liver biopsy was performed before and after 6 months of treatment and again after 6 months of follow-up. Results: Twenty-nine of the 31 patients completed 6 months of therapy. Two patients discontinued therapy after 2 and 3 months of treatment. Serum alanine aminotransferase levels returned to normal in 22 (71%) patients. Fifteen (48%) of the 31 patients cleared HCV-RNA from their serum. Only four patients experienced a worsening of their psychiatric illness during treatment. Interferon therapy was discontinued in two of these patients. Conclusions: Patients with a co-existent psychiatric illness and chronic HCV can be treated successfully with interferon-alpha with the active participation of a psychiatrist and the maintenance of psychotropic drug therapy during interferon treatment.
Articolo in rivista - Articolo scientifico
psychiatric illness; HCV; interferon;
English
165
168
4
Van Thiel, D., Friedlander, L., Molloy, P., Fagiuoli, S., Kania, R., & Caraceni, P. (1995). Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 7(2), 165-168.
Van Thiel, D; Friedlander, L; Molloy, P; Fagiuoli, S; Kania, R; Caraceni, P
File in questo prodotto:
File Dimensione Formato  
Van Thiel DH (1995) Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness.pdf

Solo gestori archivio

Dimensione 2.16 MB
Formato Adobe PDF
2.16 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/353100
Citazioni
  • Scopus 112
  • ???jsp.display-item.citation.isi??? 93
Social impact